Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Circ Cardiovasc Imaging. 2016 Nov;9(11):e005689. doi: 10.1161/CIRCIMAGING.116.005689

PET FDG Tells a Complicated Story in the Aortic Aneurysm Wall

John A Curci 1, Joshua A Beckman 2
PMCID: PMC5289468  NIHMSID: NIHMS824370  PMID: 27903546

Abdominal aortic aneurysm (AAA) was first described in the second century by Antyllus who surgically ligated the proximal and distal ends of the aneurysm. The modern treatment of AAA began with the first AAA replacement using a homograft in 1951. Since that time, the screening, diagnostic method, surveillance, and treatment of AAA have been very-well studied and incorporated into a modern paradigm of care. The results of this work is the dramatic reduction in aneurysm-related mortality for patients who maintain care and contact with a health care provider. Indeed, in patients found to have an infrarenal aorta of 4 cm in diameter, aneurysm rupture or repair is the number 4 cause of death behind other cardiovascular, cancer, and lung disease, representing 6-8% of the total mortality 1, 2.

Epidemiological investigation has made clear the population of people most likely to have an abdominal aortic aneurysm. Major risk factors for the disease include cigarette smoking, male sex, older age, and a family history of the disease. Screening studies have identified the population in whom the balance of screening and treatment is well founded. In the first 20 years of the Gloucestershire ultrasound screening program for AAA in men aged 65 years, 4.9% of the men were found to have an aneurysm worthy of surveillance or treatment 3. The value of screening in this population has been demonstrated both for reductions in aneurysm-related mortality and total mortality by the Multicenter Aneurysm Screening Study (MASS) 4, a screening study including nearly 67,000 men. On the basis of MASS and several other screening studies, the United States Preventive Services Task Force recommended the use of ultrasound screening in ever-smoking men aged 65 to 75 years 5. Multispecialty guidelines also recommend an ultrasound-based screening for men 60 years of age or older with first degree relative with AAA 6.

The maximal AP diameter of the aorta is strongly predictive of clinical outcomes, with small aortic aneurysms being quite clinically benign. Two large surveillance studies have identified a minimum aneurysm size for consideration of aneurysm repair 7, 8. In both, subjects were enrolled with an aneurysm from 4.0 to 5.5 cm in diameter and randomly assigned to ultrasound surveillance until the aneurysm reached 5.5 cm or immediate repair. There was no difference in survival during long-term follow up suggesting deferred repair was a safe strategy 9. Recent advances in the repair of AAA have also improved outcomes. Over the last two decades, AAA repair has largely transitioned from open surgical repair to endovascular stent-graft insertion. This less invasive procedure has significantly reduced the morbidity and mortality of the procedure while not diminishing the survival of these patients years later 10. Moreover, the investigations showing the efficacy of stent-grafting also reconfirmed the size criteria and made clear that treating patients too sick for open repair with an endovascular approach did not reduce mortality 11. Indeed, an important question in this field is can we improve upon these results?

Since the visionary investigator, M. David Tilson, recognized AAA as a pathologic entity distinct from atherosclerosis, the understanding of the specific pathophysiologic processes that result in aortic wall degeneration have been developed and refined. The unique histologic features of AAA include remodeling of the medial and adventitial extracellular matrix and a transmural inflammatory infiltrate. Elaboration of matrix proteinases by the inflammatory infiltrate is hypothesized as one of the mechanisms of aortic matrix degeneration. This process provides many opportunities for the rational development of diagnostic and therapeutic techniques for this disease.

Fine histologic analysis of aneurysm tissues demonstrates marked heterogeneity of the inflammation and structure of the aneurysm wall.12 One opportunity for 18FDG-PET as employed by Huang and colleagues 13 in this issue of Circulation: Cardiovascular Imaging, is to refine our understanding of the heterogeneity of the degenerative process in vivo in small aortic aneurysms. The authors demonstrate a varied distribution of the 18FDG uptake in the aortic wall and correlate those areas of increased metabolic activity to regions of high transmural stress using finite element analysis. It was particularly interesting that areas of high wall stress in association with thick intraluminal laminar thrombus (ILT) are predictive of high uptake of FDG. This linkage is supported by prior observations associating ILT volume with more rapid AAA growth.14

Of course, these results are a first step into the development of a clinically useful predictive test that will require validation and longitudinal study. The investigators analyzed over 9,000 data points (octants) which provided substantial statistical power, but these were generated through segmentation of the imaging, of only 21 patients. There was not a clear a priori rationale for the choice of a thrombus to wall ratio of 0.67 which was present in fewer than 12% of the octants analyzed (16 patients), but forms the most dramatic correlations between wall stress and inflammation. Finally, predictive features for growth need to be generated and longitudinally validated which can identify patients that are at higher risk for progression and rupture. These may be areas where, for example, there is low stress, but inappropriately high 18FDG-PET activity suggesting degenerative activity.

While these are important data, translating this information to enhance the care of patients with aneurysms is tempered by recent systematic reviews of 18FDG-PET in AAA which suggest poor predictive value with respect to aneurysm growth and rupture.15, 16 It may be overly simplistic to assume that all mural inflammation in an AAA is pathologic, and advances that may permit phenotyping the inflammation may be necessary to distinguish between pathologic and compensatory processes. Furthermore, the cells labeled by the 18FDG in vascular disease may not necessarily be inflammatory cells,17 as other imaging modalities for inflammation only correlate modestly with PET in the AAA wall.18

Nevertheless, there remains promise for PET imaging to both improve patient management and advance our understanding of this complex disease. As seen in this study, the predictive information obtained by PET with regard to wall stress was substantially enhanced by accounting for ILT, suggesting a variety of inter-related factors are important to the pathological process. Future studies which include longitudinal evaluation, possibly in combination with circulating markers of disease, may extend the findings of this study to predict the expansion of small AAA.

The study of detection and treatment of AAA in large populations has substantially optimized current patient management based on maximal diameter. However, there remains room for improvement. There are patients who have AAA rupture at a size smaller than that recommended and there are patients that do not rupture until reaching a much larger diameter. The decision to repair at 5.5 cm is based on a balancing of population risks and benefits of the aneurysm and repair. The question now is whether care can be further personalized to improve outcomes. This personalization may take on increased importance as medical therapy for small aortic aneurysms is developed.19 Ongoing research is investigating the role of determining outcomes based on patient size, aneurysmal rate of expansion, systemic inflammation, and biomarkers of extracellular matrix homeostasis or proteolysis. Novel imaging methods have also begun to expand our understanding of the pathophysiology of AAA and may provide an additional window into choosing the right timing and modality of repair. It is in this light that the report of Huang and colleagues adds to our current understanding.

Acknowledgments

Sources of Funding: This work was supported by grants from the NIH (JC: R01AG037120 and JB: R01HL131977).

Footnotes

Disclosures: Joshua Beckman: Consulting: Merck, Astra Zeneca, Bristol Myers Squibb, Sanofi, Abbott Vascular. Research Grant: Bristol Myers Squibb, Merck. Boards: VIVA Physicians. Ownership: Janacare

References

  • 1.United Kingdom ETI. Greenhalgh RM, Brown LC, Powell JT, Thompson SG, Epstein D, Sculpher MJ. Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med. 2010;362:1863–71. doi: 10.1056/NEJMoa0909305. [DOI] [PubMed] [Google Scholar]
  • 2.Lederle FA, Freischlag JA, Kyriakides TC, Matsumura JS, Padberg FT, Jr, Kohler TR, Kougias P, Jean-Claude JM, Cikrit DF, Swanson KM Group OVACS. Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N Engl J Med. 2012;367:1988–97. doi: 10.1056/NEJMoa1207481. [DOI] [PubMed] [Google Scholar]
  • 3.Darwood R, Earnshaw JJ, Turton G, Shaw E, Whyman M, Poskitt K, Rodd C, Heather B. Twenty-year review of abdominal aortic aneurysm screening in men in the county of Gloucestershire, United Kingdom. J Vasc Surg. 2012;56:8–13. doi: 10.1016/j.jvs.2011.12.069. [DOI] [PubMed] [Google Scholar]
  • 4.Thompson SG, Ashton HA, Gao L, Buxton MJ, Scott RA Multicentre Aneurysm Screening Study G. Final follow-up of the Multicentre Aneurysm Screening Study (MASS) randomized trial of abdominal aortic aneurysm screening. Br J Surg. 2012;99:1649–56. doi: 10.1002/bjs.8897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.LeFevre ML Force USPST. Screening for abdominal aortic aneurysm: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161:281–90. doi: 10.7326/M14-1204. [DOI] [PubMed] [Google Scholar]
  • 6.Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr, White CJ, White J, White RA, Antman EM, Smith SC, Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–654. doi: 10.1161/CIRCULATIONAHA.106.174526. [DOI] [PubMed] [Google Scholar]
  • 7.Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, Ballard DJ, Messina LM, Gordon IL, Chute EP, Krupski WC, Busuttil SJ, Barone GW, Sparks S, Graham LM, Rapp JH, Makaroun MS, Moneta GL, Cambria RA, Makhoul RG, Eton D, Ansel HJ, Freischlag JA, Bandyk D. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346:1437–44. doi: 10.1056/NEJMoa012573. [DOI] [PubMed] [Google Scholar]
  • 8.Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346:1445–52. doi: 10.1056/NEJMoa013527. [DOI] [PubMed] [Google Scholar]
  • 9.Powell JT, Brown LC, Forbes JF, Fowkes FG, Greenhalgh RM, Ruckley CV, Thompson SG. Final 12-year follow-up of surgery versus surveillance in the UK Small Aneurysm Trial. Br J Surg. 2007;94:702–8. doi: 10.1002/bjs.5778. [DOI] [PubMed] [Google Scholar]
  • 10.Beckman JA. Is the dream of EVAR over? N Engl J Med. 2012;367:2041–3. doi: 10.1056/NEJMe1211163. [DOI] [PubMed] [Google Scholar]
  • 11.United Kingdom ETI. Greenhalgh RM, Brown LC, Powell JT, Thompson SG, Epstein D. Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med. 2010;362:1872–80. doi: 10.1056/NEJMoa0911056. [DOI] [PubMed] [Google Scholar]
  • 12.Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest. 1998;102:1900–10. doi: 10.1172/JCI2182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Huang Y, Teng Z, Elkhawad M, Tarkin JM, Joshi N, Boyle JR, Buscombe JR, Fryer TD, Zhang Y, Park AY, Wilkinson IB, Newby DE, Gillard JH, Rudd JH. High structural stress and presence of intraluminal thrombus predict abdominal aortic aneurysm 18F-FDG uptake: Insights from biomechanics. Circulation Cardiovascular imaging. 2016;9:e004656. doi: 10.1161/CIRCIMAGING.116.004656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Parr A, McCann M, Bradshaw B, Shahzad A, Buttner P, Golledge J. Thrombus volume is associated with cardiovascular events and aneurysm growth in patients who have abdominal aortic aneurysms. Journal of Vascular Surgery. 2011;53:28–35. doi: 10.1016/j.jvs.2010.08.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Jalalzadeh H, Indrakusuma R, Planken RN, Legemate DA, Koelemay MJW, Balm R. Inflammation as a Predictor of Abdominal Aortic Aneurysm Growth and Rupture: A Systematic Review of Imaging Biomarkers. European Journal of Vascular and Endovascular Surgery. 2016;52:333–342. doi: 10.1016/j.ejvs.2016.05.002. [DOI] [PubMed] [Google Scholar]
  • 16.Timur UT, van Herwaarden JA, Mihajlovic D, De Jong P, Mali W, Moll FL. 18F-FDG PET scanning of abdominal aortic aneurysms and correlation with molecular characteristics: a systematic review. EJNMMI Research. 2015;5:1–10. doi: 10.1186/s13550-015-0153-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Sadeghi MM. (18)F-FDG PET and Vascular Inflammation; Time to Refine the Paradigm? Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2015;22:319–324. doi: 10.1007/s12350-014-9917-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.McBride OMB, Joshi NV, Robson JMJ, MacGillivray TJ, Gray CD, Fletcher AM, Dweck MR, van Beek EJR, Rudd JHF, Newby DE, Semple SI. Positron Emission Tomography and Magnetic Resonance Imaging of Cellular Inflammation in Patients with Abdominal Aortic Aneurysms. European Journal of Vascular and Endovascular Surgery. 2016;51:518–526. doi: 10.1016/j.ejvs.2015.12.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Baxter BT, Matsumura J, Curci J, McBride R, Blackwelder WC, Liu X, Larson L, Terrin ML. Non-invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA(3)CT): Design of a Phase IIb, placebo-controlled, double-blind, randomized clinical trial of doxycycline for the reduction of growth of small abdominal aortic aneurysm. Contemporary clinical trials. 2016;48:91–8. doi: 10.1016/j.cct.2016.03.008. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES